Bristol To Overcome Sprycel Uptake “Resistance” By Encouraging Faster Switching
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb reports modest sales of $25 million for Sprycel during the oncologic’s first six months on the market.
You may also be interested in...
Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion
Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.
Novartis Pegs Combined Market For Tasigna And Gleevec At $3.5 Billion
Firm says market for chronic myeloid leukemia therapies will be further differentiated pending additional studies of Tasigna.
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: